BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Classen Immunotherapies Inc. 

6517 Montrose Avenue

Baltimore  Maryland   21212  U.S.A.
Phone: 410-377-4549 Fax: 410-377-8526


SEARCH JOBS




Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Classen Immunotherapies Inc. Release: Autism Epidemic Linked to Epidemic of Vaccine Induced Diabetes 7/12/2013 10:01:32 AM
Classen Immunotherapies Inc. Release: Further Evidence Epidemics of both Type 1 Diabetes (insulin dependent) and Type 2 Diabetes/Obesity are Linked to Immunization 9/1/2011 10:44:56 AM
Classen Immunotherapies Inc. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization 8/26/2008 10:32:55 AM
Classen Immunotherapies Inc. Release: Vaccine Induced Inflammation Linked to Epidemic of Type 2 Diabetes and Metabolic Syndrome Japanese and Other Ethnic Minorities at Increased Risk 4/4/2008 10:44:20 AM
Classen Immunotherapies Inc. Files Patent Infringement Suit Against King Pharmaceuticals And Elan Corporation PLC (ELN); Classen Initiates Program For Early Generic Introduction Of The Defendants' Drugs 10/19/2005 5:12:18 PM